194 related articles for article (PubMed ID: 23946481)
1. An essential type I nitroreductase from Leishmania major can be used to activate leishmanicidal prodrugs.
Voak AA; Gobalakrishnapillai V; Seifert K; Balczo E; Hu L; Hall BS; Wilkinson SR
J Biol Chem; 2013 Oct; 288(40):28466-76. PubMed ID: 23946481
[TBL] [Abstract][Full Text] [Related]
2. Targeting the substrate preference of a type I nitroreductase to develop antitrypanosomal quinone-based prodrugs.
Hall BS; Meredith EL; Wilkinson SR
Antimicrob Agents Chemother; 2012 Nov; 56(11):5821-30. PubMed ID: 22948871
[TBL] [Abstract][Full Text] [Related]
3. Evaluating aziridinyl nitrobenzamide compounds as leishmanicidal prodrugs.
Voak AA; Seifert K; Helsby NA; Wilkinson SR
Antimicrob Agents Chemother; 2014; 58(1):370-7. PubMed ID: 24165190
[TBL] [Abstract][Full Text] [Related]
4. Exploiting the drug-activating properties of a novel trypanosomal nitroreductase.
Hall BS; Wu X; Hu L; Wilkinson SR
Antimicrob Agents Chemother; 2010 Mar; 54(3):1193-9. PubMed ID: 20028822
[TBL] [Abstract][Full Text] [Related]
5. Trypanocidal activity of nitroaromatic prodrugs: current treatments and future perspectives.
Wilkinson SR; Bot C; Kelly JM; Hall BS
Curr Top Med Chem; 2011; 11(16):2072-84. PubMed ID: 21619510
[TBL] [Abstract][Full Text] [Related]
6. Studies on the nitroreductase prodrug-activating system. Crystal structures of complexes with the inhibitor dicoumarol and dinitrobenzamide prodrugs and of the enzyme active form.
Johansson E; Parkinson GN; Denny WA; Neidle S
J Med Chem; 2003 Sep; 46(19):4009-20. PubMed ID: 12954054
[TBL] [Abstract][Full Text] [Related]
7. Discovery of potent nitrotriazole-based antitrypanosomal agents: In vitro and in vivo evaluation.
Papadopoulou MV; Bloomer WD; Rosenzweig HS; O'Shea IP; Wilkinson SR; Kaiser M; Chatelain E; Ioset JR
Bioorg Med Chem; 2015 Oct; 23(19):6467-76. PubMed ID: 26344593
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and structure-activity relationships of nitrobenzyl phosphoramide mustards as nitroreductase-activated prodrugs.
Hu L; Wu X; Han J; Chen L; Vass SO; Browne P; Hall BS; Bot C; Gobalakrishnapillai V; Searle PF; Knox RJ; Wilkinson SR
Bioorg Med Chem Lett; 2011 Jul; 21(13):3986-91. PubMed ID: 21620697
[TBL] [Abstract][Full Text] [Related]
9. Assessing the essentiality of Leishmania donovani nitroreductase and its role in nitro drug activation.
Wyllie S; Patterson S; Fairlamb AH
Antimicrob Agents Chemother; 2013 Feb; 57(2):901-6. PubMed ID: 23208716
[TBL] [Abstract][Full Text] [Related]
10. Studies relating to the synthesis, enzymatic reduction and cytotoxicity of a series of nitroaromatic prodrugs.
Burke PJ; Wong LC; Jenkins TC; Knox RJ; Meikle IT; Stanforth SP
Bioorg Med Chem Lett; 2016 Dec; 26(24):5851-5854. PubMed ID: 27876476
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and evaluation of potential prodrugs of DFMO for reductive activation.
Yang Y; Voak A; Wilkinson SR; Hu L
Bioorg Med Chem Lett; 2012 Nov; 22(21):6583-6. PubMed ID: 23031595
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation.
Jiang Y; Han J; Yu C; Vass SO; Searle PF; Browne P; Knox RJ; Hu L
J Med Chem; 2006 Jul; 49(14):4333-43. PubMed ID: 16821793
[TBL] [Abstract][Full Text] [Related]
13. Activation of benznidazole by trypanosomal type I nitroreductases results in glyoxal formation.
Hall BS; Wilkinson SR
Antimicrob Agents Chemother; 2012 Jan; 56(1):115-23. PubMed ID: 22037852
[TBL] [Abstract][Full Text] [Related]
14. Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer.
Tokay E; Güngör T; Hacıoğlu N; Önder FC; Gülhan ÜG; Tok TT; Çelik A; Ay M; Köçkar F
Eur J Med Chem; 2020 Feb; 187():111937. PubMed ID: 31841727
[TBL] [Abstract][Full Text] [Related]
15. Evaluating 5-Nitrothiazoles as Trypanocidal Agents.
O'Shea IP; Shahed M; Aguilera-Venegas B; Wilkinson SR
Antimicrob Agents Chemother; 2016 Feb; 60(2):1137-40. PubMed ID: 26596950
[TBL] [Abstract][Full Text] [Related]
16. Distinct activation mechanisms trigger the trypanocidal activity of DNA damaging prodrugs.
Meredith EL; Kumar A; Konno A; Szular J; Alsford S; Seifert K; Horn D; Wilkinson SR
Mol Microbiol; 2017 Oct; 106(2):207-222. PubMed ID: 28792090
[TBL] [Abstract][Full Text] [Related]
17. Unraveling the antitrypanosomal mechanism of benznidazole and related 2-nitroimidazoles: From prodrug activation to DNA damage.
Dattani A; Drammeh I; Mahmood A; Rahman M; Szular J; Wilkinson SR
Mol Microbiol; 2021 Aug; 116(2):674-689. PubMed ID: 34061384
[TBL] [Abstract][Full Text] [Related]
18. Novel nitroimidazole derivatives evaluated for their trypanocidal, cytotoxic, and genotoxic activities.
do Vale Chaves E Mello F; Castro Salomão Quaresma BM; Resende Pitombeira MC; Araújo de Brito M; Farias PP; Lisboa de Castro S; Salomão K; Silva de Carvalho A; Oliveira de Paula JI; de Brito Nascimento S; Peixoto Cupello M; Paes MC; Boechat N; Felzenszwalb I
Eur J Med Chem; 2020 Jan; 186():111887. PubMed ID: 31787363
[TBL] [Abstract][Full Text] [Related]
19.
Semini G; Paape D; Blume M; Sernee MF; Peres-Alonso D; Calvignac-Spencer S; Döllinger J; Jehle S; Saunders E; McConville MJ; Aebischer T
mBio; 2020 Jun; 11(3):. PubMed ID: 32487758
[No Abstract] [Full Text] [Related]
20. Novel 3-nitro-1H-1,2,4-triazole-based amides and sulfonamides as potential antitrypanosomal agents.
Papadopoulou MV; Bloomer WD; Rosenzweig HS; Chatelain E; Kaiser M; Wilkinson SR; McKenzie C; Ioset JR
J Med Chem; 2012 Jun; 55(11):5554-65. PubMed ID: 22550999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
